BRIEF OVERVIEW OF CLINICAL RESEARCHES OF ANTI-CANCER ACTIVITY OF

UC Irvine Anti-Cancer Challenge Raises Over $974,736 for Cancer Research; UCI Pharmacy's Anti-Cancer Challenge Team Contributes $6,570 – UCI School of Pharmacy & Pharmaceutical Sciences

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

Discovery of drug candidate to potentially tackle ER-positive breast cancer - Monash University

Clinical Trial Roy - BioCanRx

Clinical Trials for Bladder Cancer Roswell Park Comprehensive Cancer Center - Buffalo, NY

Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer drug - Express Pharma

Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy - ScienceDirect

The Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis

CStone Pharmaceuticals releases Phase 3 GEMSTONE-303 clinical trial data of anti-PD-L1 monoclonal antibody sugemalimab, for the treatment of gastric cancer

Safeguarding COVID-19 and cancer management

Results of the Asian Subgroup in Phase 3 Clinical Study of Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at ESMO Asia 2023-Media

Study overview of pre-clinical, clinical and omics studies using

Frontiers in Clinical Drug Research - Anti-Cancer Agents